TMCnet News

Bavencio Drug Analysis 2018: A Fully Human MAb Targeting the PD-L1 Protein - ResearchAndMarkets.com
[February 21, 2018]

Bavencio Drug Analysis 2018: A Fully Human MAb Targeting the PD-L1 Protein - ResearchAndMarkets.com


The "Drug Analysis: Bavencio" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells (Keir et al., 2008; Zhang et al., 2009; Zitvogel and Kroemer, 2012). By inhibiting the PD-1/PD-L1 interaction, Bavencio reduces the ability of the tumor to evade immunesystem targeting, and enables the activation of T cells and the adaptive immune system (Avelumab fact sheet, 2015; Pardoll, 2012).



In addition, preclinical and clinical studies have suggested that drugs targeting the PD-1/PD-L1 pathway may have fewer side effects than other immune checkpoint inhibitors (Raufi and Klempner, 2015; Brahmer et al., 2012).

Product Profiles


  • Bavencio: Head and neck cancer
  • Bavencio: Ovarian cancer
  • Bavencio: Bladder cancer
  • avelumab: Renal cell cancer (RCC)
  • avelumab: Non-small cell lung cancer (NSCLC)
  • avelumab: Gastric cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pkfqsh/bavencio_drug?w=4


[ Back To TMCnet.com's Homepage ]